• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

    4/5/25 9:00:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHVN alert in real time by email

    SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation.

    (PRNewsfoto/BIOHAVEN LTD)

    Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, "We are excited to highlight our clinical and scientific progress at the AAN Annual Meeting, including 3 oral presentations and 10 poster presentations, emphasizing Biohaven's innovation, leadership and commitment to developing potential first-in-class therapies for debilitating neurological disorders with inadequate or no treatment options. The team at Biohaven has been working urgently to advance our next-generation medicines as we aim to transform the way these diseases are treated. We look forward to achieving critical value-creating milestones throughout 2025 as we advance these assets across multiple high unmet need indications."

    The complete list of Biohaven's accepted abstracts is below. Full abstracts can be viewed online at https://index.mirasmart.com/AAN2025/.

    Oral Presentations:

    BHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson's Disease Mouse Model

    S4: Movement Disorders: Basic Science

    Sunday 4/6/25 1:00-3:00pm (2:00-2:12pm)

    Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine

    S11: Pain

    Monday 4/7/25 11:15am-12:15pm (11:51am-12:03pm)

    Novel Bispecific Degrader BHV-1310 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models including Nonhuman Primates

    S18.009

    Monday 4/7/25 1:00-3:00pm (2:36-2:48pm)

    Poster Presentations:

    A Qualitative Assessment of the Epilepsy Patient Experience Through Social Media and Web-Based Forums

    P2: Epilepsy/Clinical Neurophysiology (EEG): Clinical Outcomes in Epilepsy

    Sunday 4/6/25 8:00-9:00am

    Novel Bispecific Degrader BHV-1310 Eliminates Intravascular and Interstitial IgG within Multiple Organs and Anatomical Structures Including the Neuromuscular Junction

    P4: Autoimmune Neurology: Peripheral Autoimmune Neurology

    Sunday 4/6/25 5:00-6:00pm

    Comparative Effectiveness of Troriluzole Versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching Methods

    P6: Movement Disorders: Ataxia 1

    Monday 4/7/25 11:45-12:45

    BHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of Migraine

    P7: Headache: Advances in Headache Treatment 1

    Monday 4/7/25 5:00-6:00pm

    Re-weighting MDS-UPDRS Parts II and III Items to Improve Assessment of Motor Decline in Untreated Parkinson's Disease

    P7: Movement Disorders: Parkinson's Disease Management

    Monday 4/7/25 5:00-6:00pm

    Re-weighting MDS-UPDRS Part II and PDQ-39 Items to Detect Maximal Decline in Activities of Daily Living in Untreated Parkinson's disease

    P7: Movement Disorders: Parkinson's Disease Management

    Monday 4/7/25 5:00-6:00pm

    A Modern Design for a Phase 2/3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures

    P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials

    Tuesday 4/8/25 8:00-9:00am

    BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies

    P9: General Neurology: New, Potential, and Innovative Treatments 1

    Tuesday 4/8/25 11:45am-12:45pm

    Phase 1 Multiple Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator

    P9: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms and Pharmacology

    Tuesday 4/8/25 11:45am-12:45pm

    Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)

    P12: Movement Disorders: Ataxia 2

    Wednesday 4/9/25 11:45-12:45

    Posters and presentations will be available on the Posters and Presentations page after the conference at www.biohaven.com.   

    About Biohaven 

    Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer.

    Forward-looking Statements

    This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate", "potential first-in-class", "disrupt", "potentially revolutionize", "groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange  Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Jennifer Porcelli

    Vice President, Investor Relations

    [email protected]

    +1 (201) 248-0741

    Media Contact:

    Mike Beyer

    Sam Brown Inc.

    [email protected]

    +1 (312) 961-2502

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-presents-data-across-innovative-neuroscience-portfolio-at-the-2025-american-academy-of-neurology-aan-annual-meeting-302421403.html

    SOURCE Biohaven Ltd.

    Get the next $BHVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHVN

    DatePrice TargetRatingAnalyst
    2/11/2025$65.00Buy
    Deutsche Bank
    9/16/2024$57.00Buy
    Jefferies
    9/4/2024$55.00Outperform
    Bernstein
    7/24/2024$58.00Overweight
    Morgan Stanley
    2/16/2024$62.00Outperform
    RBC Capital Mkts
    2/6/2024$59.00Buy
    UBS
    12/22/2023$50.00Buy
    H.C. Wainwright
    12/8/2023$58.00Outperform
    Robert W. Baird
    More analyst ratings

    $BHVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on Biohaven with a new price target

      Deutsche Bank initiated coverage of Biohaven with a rating of Buy and set a new price target of $65.00

      2/11/25 7:01:45 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Biohaven with a new price target

      Jefferies initiated coverage of Biohaven with a rating of Buy and set a new price target of $57.00

      9/16/24 7:22:04 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernstein initiated coverage on Biohaven with a new price target

      Bernstein initiated coverage of Biohaven with a rating of Outperform and set a new price target of $55.00

      9/4/24 7:31:23 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biohaven Announces Investment up to $600 Million by Oberland Capital

      Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales$250 million to be funded at closing$150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expensesNEW HAVEN, Conn., April 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseas

      4/28/25 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

      SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer

      4/5/25 9:00:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BHVN
    SEC Filings

    See more

    $BHVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BHVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Childs John W bought $996,238 worth of shares (32,700 units at $30.47) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 7:01:52 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Childs John W bought $2,999,970 worth of shares (73,170 units at $41.00) (SEC Form 4)

      4/A - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 6:59:47 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $1,042,393 worth of shares (29,000 units at $35.94) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      12/31/24 7:00:14 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Biohaven Ltd. (0001935979) (Filer)

      5/7/25 5:18:11 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Biohaven Ltd. (0001935979) (Filer)

      4/28/25 7:59:17 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Biohaven Ltd.

      DEFA14A - Biohaven Ltd. (0001935979) (Filer)

      3/18/25 4:48:49 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/14/24 3:06:46 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/12/24 1:20:24 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/4/24 11:16:33 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Antonijevic Irina

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:16:02 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Heffernan Michael Thomas

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:15:04 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bailey Gregory

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:14:32 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Financials

    Live finance-specific insights

    See more
    • Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

      Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

      9/23/24 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

      Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

      9/20/24 7:09:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

      Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

      3/22/23 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

      Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

      5/12/23 4:30:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care